How much funding has Betalin Therapeutics raised?

Betalin Therapeutics has raised $8.1M in total funding, most recently a Series A round.

Who are Betalin Therapeutics's investors?

Betalin Therapeutics's investors include European Innovation Council Fund, Horizon 2020.

When was Betalin Therapeutics founded?

Betalin Therapeutics was founded in 2015.

Where is Betalin Therapeutics headquartered?

Betalin Therapeutics is headquartered in Jerusalem.

What industry is Betalin Therapeutics in?

Betalin Therapeutics operates in Biotech, Medical Devices.

Betalin Therapeutics

Liberating from Insulin Dependency

Jerusalem · Founded 2015 · $8.1M raised

Biotech

Medical Devices

Headquarters: Jerusalem
Founded: 2015
Business Model: B2B
Website: betalintherapeutics.com

Total Funding: $8.1M
Last Round: $565K Series AJan 2022
Rounds: 4

About

Betalin Therapeutics is developing a bio-engineered micro-pancreas (EMP) that combines stem-cell-derived insulin-producing cells with a supportive tissue scaffold (micro-organ matrix) to treat diabetes via a single subcutaneous transplant. Licensed from the Hebrew University in 2015 and led by CEO Racheli Ofir, the Israel-based biotech aims to eliminate the lifelong immune suppression and low engraftment rates seen with conventional islet-cell transplants.

Summary

Betalin Therapeutics is a Biotech company based in Jerusalem, founded in 2015. It has raised $8.1M in total across 4 rounds, most recently a $565K Series A round in Jan 2022. Investors include European Innovation Council Fund and Horizon 2020.